Despite the critical role that
TGF-beta plays in renal
fibrosis, transgenic mice that overexpress human latent
TGF-beta1 in the skin exhibit normal renal histology and function even though circulating levels of latent
TGF-beta1 are an order of magnitude higher than wild-type animals. In fact, latent
TGF-beta1 seems to protect against renal
inflammation in a model of
ureteral obstruction. It is unknown, however, whether latent
TGF-beta1 also has this effect in immunologically mediated forms of renal disease such as
anti-GBM crescentic
glomerulonephritis. We induced
anti-GBM disease in wild-type and transgenic mice overexpressing latent
TGF-beta1 in keratinocytes. After 14 days, wild-type mice developed progressive crescentic
glomerulonephritis with severe renal
inflammation and
fibrosis. In transgenic mice,
proteinuria was reduced by 50%, renal function was preserved, and the formation of glomerular crescents was suppressed by 70%. In addition, transgenic animals had reduced renal
inflammation, evidenced by a 70% decrease in the accumulation of T cells and macrophages, and reduced expression of renal IL-1beta,
TNFalpha, and MCP-1 by 70 to 80%. Progressive renal
fibrosis was also prevented in the transgenic mice, and these protective effects were associated with elevated levels of latent, but not active,
TGF-beta1 in plasma and renal tissue. Renal Smad7 was up-regulated and both
NF-kappaB and
TGF-beta/Smad2/3 activation were suppressed. In conclusion, mice overexpressing latent
TGF-beta1 in the skin were protected against
anti-GBM crescentic
glomerulonephritis, possibly via Smad 7-mediated inhibition of
NF-kappaB-dependent renal
inflammation and
TGF-beta/Smad2/3-dependent
fibrosis.